Summary
Biomarkers provide a dynamic and powerful approach to understanding the spectrum of neurological disease with applications in observational and analytic epidemiology, randomized clinical trials, screening and diagnosis and prognosis. Defined as alterations in the constituents of tissues or body fluids, these markers offer the means for homogeneous classification of a disease and risk factors, and the can extend our base information about the underlying pathogenesis of disease. Biomarkers can also reflect the entire spectrum of disease from the earliest manifestations to the terminal stages. This brief review describes the major uses of biomarkers in clinical investigation. Careful assessment of the validity of biomarkers is required with respect to the stage of disease. Causes of variability in the measurement of biomarkers range from the individual to the laboratory. Issues that affect the analysis of biomarkers are discussed along with recommendations on how to deal with bias and confounding.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Hulka BS. Overview of biological markers. In: Biological markers in epidemiology (Hulka BS, Griffith JD, Wilcosky TC, eds), pp 3–15. New York: Oxford University Press, 1990.
Naylor S. Biomarkers: current perspectives and future prospects.Expert Rev Mol Diagn 3: 525–529, 2003.
Perera FP, Weinstein IB. Molecular epidemiology: recent advances and future directions.Carcinogenesis 21: 517–524, 2000.
Gordis L. Epidemiology and public policy. In: Epidemiology (Gordis L, ed), pp 247–256. Philadelphia: W.B. Saunders, 1996.
Verbeek MM, De Jong D, Kremer HP. Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases.Ann Clin Biochem 40: 25–40, 2003.
Galasko D. New approaches to diagnose and treat Alzheimer’s disease: a glimpse of the future.Clin Geriatr Med 17: 393–410, 2001.
Rohlff C. Proteomics in neuropsychiatric disorders.Int J Neuropsychopharmacol 4: 93–102, 2001.
Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs.J Neurol Sci 184: 101–122, 2001.
Schulte PA. A conceptual and historical framework for molecular epidemiology. In: Molecular epidemiology: principles and practices (Schulte PA, Perera FP, eds), pp 3–44. San Diego: Academic Press, 1993.
Merikangas K. Genetic epidemiology: bringing genetics to the population—the NAPE Lecture 2001.Acta Psychiatr Scand 105: 3–13, 2002.
Muller U, Graeber MB. Neurogenetic diseases: molecular diagnosis and therapeutic approaches.J Mol Med 74: 71–84, 1996.
Mayeux R. Epidemiology of neurodegeneration.Annu Rev Neurosci 26: 81–104, 2003.
Schulte PA, Perera FP. Validation. In: Molecular epidemiology: principles and practices (Schulte PA, Perera FP, eds), pp 79–107. San Diego: Academic Press, 1993.
Pepe MS, Thompson ML. Combining diagnostic test results to increase accuracy.Biostatistics 1: 123–140, 2000.
Thompson ML, Zucchini W. On the statistical analysis of ROC curves.Stat Med 8: 1277–1290, 1989.
Mayeux R, Saunders AM, Shea S et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s Disease Centers Consortium on apolipoprotein E and Alzheimer’s disease.N Engl J Med 338: 506–511, 1998.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mayeux, R. Biomarkers: Potential uses and limitations. Neurotherapeutics 1, 182–188 (2004). https://doi.org/10.1602/neurorx.1.2.182
Issue date:
DOI: https://doi.org/10.1602/neurorx.1.2.182